Executive Summary

Valued at 31.3 USD Billion in 2025, the Insulin Delivery Devices Market is forecast to reach 66.5 USD Billion by 2035, expanding at a CAGR of 7.82%. Momentum is already visible in 2026, with the market valued at an estimated 33.8 USD Billion, as the 2025-2035 window captures sustained growth in diagnosed diabetes prevalence and expanding reimbursement for advanced delivery technology.

Growth is driven by rising incidence of type 1 and type 2 diabetes requiring intensive insulin therapy, and by payer and regulatory support for automated insulin delivery under the US FDA’s device clearance pathway. Homecare self-administration and pump-based dosing precision are displacing conventional syringe-based regimens across developed and emerging health systems, while Bluetooth- and NFC-enabled connected devices gain share as clinicians favor data-linked dosing over manual record-keeping.

Europe held 28.0% of the market in 2025, anchored by Germany, France and the United Kingdom, while North America and Asia-Pacific carry the largest diabetic patient bases across the United States, China and India. Insulin pens led product demand with 52.44% share, insulin pumps recorded the fastest adoption at an 11.33% CAGR, and adults remained the dominant age cohort at 66.24% of use.

Device cost and inconsistent reimbursement for pump and connected-sensor systems remain the principal constraint on broader conversion from syringes, particularly outside employer-sponsored insurance markets, and EU MDR recertification adds cost for legacy pen and syringe manufacturers. Competition is moderately consolidated, with device makers competing on consumable pull-through, connectivity features and clinician relationships rather than price alone.

Margin concentrates at the device-OEM stage, where proprietary pump reservoirs, sensor integration and cartridge consumables lock patients into a single ecosystem long after initial hardware sale, while component suppliers and CDMOs further upstream capture thinner, volume-based margin. The most consequential shift through 2035 is the migration from syringe and conventional pen therapy toward connected, algorithm-driven automated insulin delivery, evidenced by the 12.77% CAGR projected for Bluetooth- and NFC-enabled devices against 7.82% for the market overall, alongside homecare settings’ rise as the leading end-user category.

Key Takeaways

• The Insulin Delivery Devices Market was valued at USD 31.339 Billion in 2025 and is projected to reach USD 66.531 Billion by 2035, a 7.82% CAGR.
• Insulin Pens led product type with a 52.44% share in 2025.
• Insulin Pumps are the fastest-growing product type, projected at an 11.33% CAGR through 2035.
• Europe held a 28% regional share, anchored by Germany, France, and the United Kingdom.
• Homecare Settings, the leading end-user segment at 43.67% share, are also expanding fastest at a 10.45% CAGR.
• EU MDR recertification burden weighs on legacy device manufacturers as a persistent restraint.

Market Definition and Scope

The Insulin Delivery Devices Market covers insulin pens, insulin pumps, insulin syringes, needle-free injectors and jet injectors used for insulin administration across pediatric, adult and geriatric diabetes patients, valued at USD 31.339 Billion in 2025. Scope spans connected (Bluetooth/NFC) and non-connected device classes, hospital, retail and online pharmacy and diabetes-clinic distribution channels, and homecare, hospital, specialty-clinic and ambulatory-surgical-centre end users, evaluated under prevailing market-access and reimbursement pathways governing insulin as standard of care for Type 1 and Type 2 diabetes management.

Excluded are insulin formulations and biosimilar insulin products, which carry pharmaceutical rather than device classification and a separate regulatory pathway. Stand-alone continuous glucose monitors sold without integrated delivery hardware, oral antidiabetic therapies, and non-insulin injectable systems such as GLP-1 pens for weight management fall outside this boundary as distinct indication and reimbursement categories.

Industry Structure

Insulin delivery devices move through a seven-stage chain in which the device originator, not the raw-material supplier, sets terms. Component specialists open the chain: Ypsomed supplies pen-injector platforms (YpsoPen, UnoPen) under license to pharmaceutical sponsors, while Becton Dickinson supplies needles and cannula components to multiple OEMs. These suppliers hold engineering know-how but little pricing leverage, since their output is fungible across device brands.

The device OEM stage captures most of the value. Medtronic (MiniMed pump platform), Insulet (Omnipod patch system), Tandem Diabetes Care (t:slim X2), and the insulin manufacturers Novo Nordisk, Eli Lilly, and Sanofi integrate components into branded systems and file for regulatory clearance – FDA 510(k) or PMA for pumps, EU MDR technical documentation for CE marking. Approval status becomes the gate: once cleared, an OEM controls label claims, algorithm updates, and consumable compatibility.

From there, distributors and durable-medical-equipment (DME) suppliers move product to providers, while payers – CMS, national health systems, and pharmacy-benefit managers – set the coverage terms and reimbursement codes that determine which system a patient can actually obtain. Endocrinology clinics and diabetes educators complete the chain by prescribing and titrating therapy.

Pricing power concentrates at the OEM stage, driven by installed base and consumable lock-in: once a patient is fitted to a pump or pod platform, switching means new hardware, retraining, and payer re-authorization, so reservoirs, pods, and infusion sets recur as high-margin consumables. The thinnest margin sits with DME distributors and generic component suppliers, squeezed between OEM list pricing on one side and payer rebate demands and formulary tendering on the other.

Insulin Delivery Devices – Value Chain

`Component Supplier` (Ypsomed, BD) to `Device OEM` (Medtronic, Insulet, Tandem, Novo Nordisk, Eli Lilly, Sanofi) to `Regulatory Approval` (FDA 510(k)/PMA, EU MDR) to `Distributor / DME Supplier` to `Payer` (CMS, PBMs, national systems) to `Provider` (endocrinology clinics) to `Patient`

Pricing power: Device OEM stage (installed base + consumable lock-in). Thinnest margin: Distributor/DME stage (squeezed between OEM pricing and payer rebates).

Market Trends

Hybrid Closed-Loop Systems Are Becoming the Default Standard of Care for Type 1 Diabetes

Automated insulin delivery is displacing standalone pumps and multiple daily injection regimens as the reference treatment for type 1 diabetes. NICE technology appraisal TA943, published 19 December 2023, recommends hybrid closed loop systems on the NHS for all under-18s with type 1 diabetes and for adults meeting HbA1c or hypoglycaemia-risk thresholds, with NHS England and NHS Wales committing to a five-year phased rollout from early 2024. Endocrinologists, paediatric diabetes centres, and device manufacturers building sensor-integrated pump platforms are the direct beneficiaries. As comparable coverage decisions extend across other national health systems, demand shifts from open-loop and manual dosing hardware toward algorithm-driven, sensor-linked pump architectures through the 2025-2035 forecast period.

Reimbursement and National Procurement Mechanisms Are Reshaping Where Device Demand Concentrates

Payer and government pricing action, rather than clinical preference alone, is now a primary demand lever. Under Inflation Reduction Act Section 11407, effective 1 July 2023, Medicare Part B caps beneficiary coinsurance at USD 35 per one-month supply of insulin delivered through a DME insulin pump and waives the Part B deductible for it, lowering the out-of-pocket barrier to pump adoption for Medicare-eligible patients. Concurrently, China’s National Healthcare Security Administration ran its first insulin-exclusive Volume-Based Procurement round from May 2022, cutting average product prices 48% across 14,000 institutions. Device makers and distributors face divergent effects: US pump volume gains support from coinsurance relief, while Chinese insulin-product economics compress, redirecting competitive focus toward delivery-device differentiation.

Interoperable Device Standards Are Shortening Replacement Cycles for Pump Components

FDA’s Alternate Controller Enabled (ACE) insulin pump category, codified under 21 CFR 880.5730, and ISO 11608-1:2022 dose-accuracy requirements for needle-based injection systems are pushing manufacturers toward modular, interoperable components rather than closed single-vendor systems. This affects pump, sensor, and pen-injector makers seeking component-level FDA clearance and CE compliance rather than full-system approval. Clinicians and procurement teams gain the ability to mix ACE-cleared pumps with independently cleared CGMs, shortening component-level replacement and upgrade cycles as individual parts reach end-of-life or receive incremental clearances, sustaining unit-volume growth independent of overall patient-population expansion through 2035.

Growth Drivers and Restraints

Growth Drivers

Medicare’s $35 Insulin-Pump Coinsurance Cap Lowers the U.S. Adoption Barrier

Medicare Part B beneficiaries pay no more than USD 35 per month for insulin delivered through a covered durable medical equipment insulin pump, a cap set by Inflation Reduction Act Section 11407 and effective 1 July 2023, with the Part B deductible waived for that insulin. The Centers for Medicare & Medicaid Services administers the provision, and HHS’s Office of the Assistant Secretary for Planning and Evaluation modeled that roughly 31,000 Part B beneficiaries would have benefited had the cap applied in 2020, saving an average of USD 866 each and USD 27 Million in aggregate. The mechanism runs through the pump channel specifically: durable medical equipment insulin pumps become materially cheaper to run than multiple daily injections for the Medicare-age population, pulling North American demand toward pump-based delivery over vial-and-syringe replacement.

NICE’s Hybrid Closed-Loop Endorsement Opens NHS Funding for Automated Delivery

NICE recommended hybrid closed loop systems for NHS funding in appraisal TA943, published 19 December 2023, covering all patients under 18 with type 1 diabetes, adults with HbA1c at or above 58 mmol/mol (7.5%) or disabling hypoglycaemia despite optimal pump or continuous glucose monitoring use, and people who are pregnant or planning pregnancy. NHS England and NHS Wales committed to a phased rollout beginning in early 2024 and running over five years. The transmission is direct: a positive HTA verdict converts hybrid closed-loop hardware from a self-pay device into an NHS-commissioned technology, shifting UK tender volume toward automated insulin delivery systems and away from standalone pump or manual multiple-daily-injection regimens.

China’s Volume-Based Procurement Cuts Insulin Costs and Expands Device Pull-Through

China’s National Healthcare Security Administration ran its first insulin-exclusive National Volume-Based Procurement round, announced in November 2021 and implemented provincially from May 2022, cutting average prices 48% across human insulin and analogues from Novo Nordisk, Eli Lilly, Sanofi and seven domestic manufacturers, and covering 14,000 medical institutions with a first-year demand volume of 215 Million shots. In Guangdong Province, an interrupted time-series analysis found monthly procurement volume rose from 7.69 Million to 9.37 Million defined daily doses while cost per dose fell from CNY 11.24 to CNY 5.57. The mechanism favors volume over price: procurement-driven affordability expands the treated and insured base within China’s device and analogue segment even as per-unit revenue compresses.

Restraints

FDA Interoperability Controls Raise the Compliance Bar for New Entrants

The FDA’s interoperable glycemic controller special controls under 21 CFR 862.1356 require validated software, connectivity and device-to-device communication testing before an automated insulin delivery component can clear the U.S. market. The requirement raises the fixed engineering and clinical-validation cost of bringing a new controller, pump or sensor into an interoperable AID system, and it applies regardless of company size. The effect concentrates share with incumbents that already hold cleared components, since a new entrant must validate compatibility across the full interoperable stack rather than a single device.

Public and Private Coverage Gaps Stall Pump and CGM Uptake in Latin America

Brazil’s public health system does not provide insulin pumps or continuous glucose monitors, and private insurers routinely decline to cover them. In an observational cohort of 92 people with type 1 diabetes treated at a Brazilian public clinic, none had regular CGM access; patients relied on four to five daily capillary glucose checks, and 81.5% used long-acting insulin analogues rather than pump-based delivery. The gap is one of commercial execution rather than device availability: distributors and OEMs face a Latin American buyer base with device technology on the market but no reimbursement channel to move it into public-system patients’ hands.

Segment Analysis

By Product Type

• Insulin Pens (largest, 52.44% share) – A pre-filled or cartridge-loaded pen-shaped device that patients use to self-administer measured insulin doses through a short disposable needle

• Reusable Insulin Pens
• Disposable Insulin Pens
• Smart Insulin Pens
• Insulin Pumps (fastest-growing, 11.33% CAGR) – A small wearable device that delivers continuous, programmable insulin doses through a subcutaneous cannula without repeated manual injections

• Tethered Pumps
• Patch Pumps
• Hybrid Closed-Loop (Sensor-Augmented) Pumps

• Insulin Syringes – A traditional needle-and-barrel instrument used to draw insulin from a vial and inject a manually measured dose under the skin
• Needle-Free Injectors – A device that forces a fine, high-pressure stream of insulin through the skin without a needle, using either spring, gas, or jet mechanisms

• Spring-Based Injectors
• Gas-Powered Injectors
• Laser-Powered Injectors
• Jet Injectors – A needle-free device that propels insulin through the skin as a narrow high-velocity liquid jet driven by mechanical or gas pressure

• Spring-Powered Jet Injectors
• Gas-Powered Jet Injectors
• Others – Supplementary insulin delivery tools such as insulin patches, ports, connectors, and safety accessories used alongside the main delivery methods

• Insulin Inhalers
• Wearable Insulin Patches

Insulin pens accounted for 52.44% of the market by product type in 2025. Pens pair pre-set dosing increments with a form factor that fits a pocket or bag, cutting the training burden relative to vial-and-syringe regimens and suiting the basal-bolus schedules most type 2 patients follow. Pharmacy benefit coverage of disposable and reusable pen platforms reinforces this position at the point of prescribing. Insulin pumps are the fastest-growing product type, expanding at an 11.33% CAGR. Automated insulin delivery systems that pair pumps with continuous glucose monitors are drawing patients off multiple daily injections toward algorithm-managed dosing, and broadening payer coverage of pump therapy is lowering the switching cost.

By Technology / Connectivity

• Connected (Bluetooth / NFC) (fastest-growing, 12.77% CAGR) – Insulin pumps, smart pens, and sensors that wirelessly transmit dosing and glucose data to a paired smartphone app or receiver for tracking and dose calculation
• Smart Insulin Pens

• Reusable Smart Pens
• Disposable Smart Pens
• Connected Insulin Pumps

• Tubed Pumps
• Patch Pumps

• Bluetooth-Enabled Blood Glucose Meters
• Companion Mobile Apps
• Non-Connected / Conventional (largest, 71.45% share) – Standalone insulin delivery devices such as syringes, vials, and basic pens that operate without wireless data transmission or companion app connectivity
• Conventional Insulin Pens

• Reusable Pens
• Disposable Pens

• Insulin Syringes
• Conventional Insulin Pumps

• Tubed Pumps
• Patch Pumps
• Insulin Jet Injectors

Non-connected, conventional devices held 71.45% of the market by technology in 2025. Lower unit cost, an established manufacturing base, and routine insurance coverage keep conventional pens, pumps, and syringes the default choice, particularly for elderly patients and those newly initiating insulin therapy. Connected devices with Bluetooth or NFC dose capture are growing fastest, at a 12.77% CAGR. Smart pen caps and connected pumps that log dose timing and sync to companion apps are being adopted alongside CGM use, and payers increasingly favor devices that generate adherence data for chronic-disease management programs.

By Patient Age Group

• Pediatrics (fastest-growing, 9.34% CAGR) – Infants, children, and adolescents with diabetes who require insulin delivery devices designed with smaller dosing increments and features for caregiver-assisted or school-based use

• Neonates
• Infants and Toddlers
• Children
• Adolescents

• Adults (largest, 66.24% share) – Individuals typically aged 18 to 64 who use insulin delivery devices such as pens, pumps, or syringes to self-manage diabetes as part of daily routines including work and independent living
• Geriatrics – Older adults, often with comorbidities and reduced dexterity or vision, who use insulin delivery devices that accommodate age-related physical and cognitive limitations

Adults represented 66.24% of the market by patient age group in 2025, reflecting the concentration of type 2 diabetes diagnosis and insulin initiation in this cohort under established treatment protocols. Pediatric patients are the fastest-growing age group, at a 9.34% CAGR. Rising type 1 diabetes diagnosis in children is driving demand for pediatric-specific pens and pumps with finer dose increments, and school-based diabetes management programs are extending device access and reimbursement support to younger patients.

By Distribution Channel

• Hospital Pharmacies – In-house pharmacy units within hospitals that dispense insulin delivery devices to inpatients and discharged patients as part of clinical care

• In-patient Pharmacy
• Out-patient Pharmacy
• Retail Pharmacies (largest, 44.73% share) – Independent and chain drugstores where patients purchase insulin delivery devices over the counter or against a prescription

• Chain Pharmacies
• Independent Pharmacies
• Online Pharmacies (fastest-growing, 12.53% CAGR) – E-commerce platforms and pharmacy websites that let patients order insulin delivery devices for home delivery

• Manufacturer-run Online Stores
• Third-party E-pharmacy Platforms
• Diabetes Clinics & Centers – Specialized outpatient facilities focused on diabetes management where clinicians prescribe, dispense, and train patients on insulin delivery devices

Retail pharmacies dispensed 44.73% of insulin delivery devices in 2025, the largest distribution channel, on the strength of broad geographic coverage and pharmacy benefit manager contracts that route chronic refills through retail networks. Online pharmacies are growing fastest, at a 12.53% CAGR. Subscription-based e-pharmacy platforms and telehealth-linked prescription fulfillment are shifting routine refills away from in-person pickup, a substitution accelerated by patients who value price transparency and home delivery for a device they reorder monthly.

By End User

• Homecare Settings (largest, 43.67% share; fastest-growing, 10.45% CAGR) – The home environment where patients or caregivers self-administer insulin using pens, syringes, or pumps outside a clinical facility
• Hospitals & Specialty Clinics – Inpatient and outpatient facilities where physicians and endocrinologists manage insulin therapy for newly diagnosed, hospitalized, or complex diabetes cases

• Hospitals
• Specialty/Diabetes Clinics

• Ambulatory Surgical Centers – Outpatient facilities where same-day procedures require short-term perioperative insulin administration and glucose management for diabetic patients
• Others – Remaining end users such as diagnostic and research laboratories, academic institutes, and long-term care or elder-care facilities that administer insulin

• Academic & Research Institutes
• Diagnostic Centers
• Long-Term Care Facilities

Homecare settings accounted for 43.67% of end-user demand in 2025 and are simultaneously the fastest-growing end-user segment, at a 10.45% CAGR. Chronic, self-administered insulin therapy is structurally suited to the home, and device simplification, including prefilled pens and app-guided pumps, has removed most of the clinical oversight once required for safe self-injection. The segment’s continued acceleration reflects payer and provider preference for shifting routine diabetes management out of hospitals and specialty clinics, which reduces per-patient cost of care while keeping outcomes within guideline-recommended glycemic targets.

The axes concentrate around one profile: a connected pump, self-administered at home

The five axes describe overlapping slices of the same growth pocket rather than independent markets. The fastest-growing member on every axis – pumps, connected technology, pediatric patients, online distribution, and homecare use – points to a single converging profile: a connected insulin pump, prescribed increasingly to younger patients, refilled through online or specialty channels, and used outside a clinical setting. The distribution-channel and end-user axes are the closest to collapsing into one another, since online pharmacy growth is largely a fulfillment mechanism for homecare-based therapy rather than a distinct demand pool. Product type and technology are converging from the opposite direction, as pump volume increasingly ships connected by default, folding the technology axis into a product-type attribute over the forecast period. Adult, pen-based, retail-dispensed demand remains the largest revenue base through 2035, but it is the slower-growing base against which these converging segments are gaining share.

Application and End-Use Analysis

Hospitals

Hospitals, within the Hospitals & Specialty Clinics end-user category, administer insulin to newly diagnosed, critically ill, and perioperative diabetic patients under continuous clinical supervision. The purchasing requirement centers on rapid, error-resistant dosing: pharmacy and biomedical engineering committees specify insulin pens and pump systems with barcode-verified dosing, safety-engineered needles, and compatibility with electronic medication administration records to meet inpatient safety protocols. Procurement runs through group purchasing organizations and hospital pharmacy formularies rather than individual clinician choice, favoring vendors with established institutional contracts. Demand tracks hospitalization volume and inpatient glycemic-control protocols more than outpatient prescribing trends, giving this channel steadier, if less dynamic, unit growth than home-based use.

Specialty/Diabetes Clinics

Specialty and Diabetes Clinics, within the Hospitals & Specialty Clinics end-user category, manage insulin titration, device training, and ongoing glycemic monitoring for patients with complex or long-duration diabetes. The purchasing requirement is device flexibility: endocrinologists prescribe across insulin pens, hybrid closed-loop pumps, and connected devices based on individual patient physiology, requiring clinics to stock a broader device mix than hospital pharmacies and to maintain certified diabetes educators for pump initiation. Reimbursement coding and payer prior-authorization requirements shape which devices a clinic can dispense without delay. Rising referral volume for pump and continuous-monitoring initiation supports steady demand growth at these sites through the forecast period.

Homecare Settings

Homecare Settings, the largest end-user category in the Insulin Delivery Devices Market at 43.67% share in 2025, cover self-administration by patients and caregivers outside a clinical facility. The purchasing requirement is ease of independent use: patients and caregivers favor prefilled or cartridge-based pens, patch pumps, and connected devices with companion apps that simplify dosing, reduce injection anxiety, and support remote data sharing with a care team without in-person supervision. Retail and online pharmacy availability, insurance formulary placement, and device simplicity outweigh institutional purchasing contracts as the deciding factors here. This category also posted the fastest end-user growth, at a 10.45% CAGR, as diabetes care continues shifting toward daily self-management outside hospitals and clinics.

Regional Analysis

North America ties adoption to a reimbursement cap, not a component shortage

Medicare Part B has capped beneficiary coinsurance for pump-delivered insulin at $35 per one-month supply since 1 July 2023 under Inflation Reduction Act Section 11407, with the Part B deductible waived entirely for the benefit. HHS’s ASPE office estimated roughly 31,000 Part B beneficiaries would have qualified had the rule applied in 2020, averaging about $866 in annual savings each, near USD 27 million in aggregate relief. That single coinsurance change reset the economics of DME-channel pump prescribing for the U.S. commercial base. Canada layers provincial formulary listings on top of that U.S. driver, while Mexico’s IMSS tender purchasing sustains a lower-price public-sector tier alongside private clinics. The three markets move at different reimbursement speeds but share exposure to U.S. device-maker pricing.

Europe held 28.0% of the market in 2025 on an NHS coverage decision

At USD 8.775 Billion of the USD 31.339 Billion base, Europe was the second-largest region in 2025. NICE’s Technology Appraisal TA943, finalized 19 December 2023, recommended hybrid closed-loop systems across NHS England and NHS Wales for all under-18s with type 1 diabetes and for adults meeting HbA1c or hypoglycaemia thresholds, with a phased rollout committed from early 2024 across a five-year window. The United Kingdom’s uptake curve therefore tracks a published NHS timetable rather than open-market demand. Germany’s statutory sickness-fund reimbursement and France’s Haute Autorité de Santé listings extend coverage on separate national schedules, so the region’s growth is a sum of three distinct approval clocks rather than one EU-wide switch.

Asia-Pacific runs on volume-based procurement, not list pricing

China’s National Healthcare Security Administration ran its first insulin-only National Volume-Based Procurement round, announced November 2021 and implemented provincially from May 2022, cutting average prices 48% across human insulin and analogues from Novo Nordisk, Eli Lilly, Sanofi and seven domestic manufacturers, spanning 14,000 institutions and 215 million shots of first-year demand. In Guangdong Province alone, monthly volume rose from 7.69 million to 9.37 million DDDs while cost per DDD fell from CNY 11.24 to CNY 5.57. Japan’s PMDA approval pathway and India’s generic-heavy supply base sit at opposite ends of the region’s price spectrum, while South Korea’s device reimbursement code list is narrower than either. Volume absorbs what price concedes.

Middle East carries the highest diabetes prevalence of any IDF region; Africa carries the lowest device base

The IDF Middle East and North Africa region recorded 17.6% age-adjusted diabetes prevalence in 2024, roughly 85 million adults, the highest of any IDF region and the demand pool behind Saudi Arabia’s public procurement programmes. The IDF Africa region recorded 5.0% prevalence across 25 million adults over the same reference year, a smaller, earlier-stage treated population. South Africa’s public-sector purchasing anchors that lower base. The two sub-regions diverge on diagnosis infrastructure as much as on prevalence.

South America’s device gap is a coverage gap, not a demand gap

Brazil’s public health system, SUS, does not provide insulin pumps or continuous glucose monitors, and private insurance rarely covers either. A cohort of 92 people with type 1 diabetes at a Brazilian public clinic found none with regular CGM access; 81.5% used long-acting analogue insulin and 18.5% used NPH, delivered by four to five daily capillary checks. Argentina’s public-private mix follows a comparable pattern at smaller scale. Device penetration across the region trails diagnosed prevalence, not device availability abroad.

Country Growth Comparison

The United States set the pace on device economics, capping Medicare Part B coinsurance for DME insulin pumps at USD 35 per month under Inflation Reduction Act Section 11407, effective 1 July 2023, saving an estimated 31,000 beneficiaries about USD 866 each annually. The United Kingdom followed with NICE TA943, published 19 December 2023, recommending hybrid closed-loop systems for all under-18s with type 1 diabetes and eligible adults, with NHS England and NHS Wales phasing rollout over five years from early 2024. China compressed pricing rather than volume: its first insulin-specific National Volume-Based Procurement round cut average prices 48% across human insulin and analogues from May 2022, covering 14,000 institutions. Brazil’s public system (SUS) excludes pumps and CGM from routine coverage, leaving device uptake dependent on private pay. Saudi Arabia and South Africa sit within the IDF Middle East and North Africa region, whose 17.6% age-adjusted diabetes prevalence is the highest of any IDF region.

Competitive Landscape

The insulin delivery devices market is moderately consolidated, with pen, pump, and biosimilar insulin manufacturing concentrated among a small set of established players while injector and infusion-set specialists fill adjacent niches.

Competition centers on installed base and consumable lock-in: pump platforms lock patients into proprietary reservoirs, infusion sets, and sensor-integration ecosystems, so switching costs rather than device price alone determine retention. Regulatory approval status and label breadth are the second axis – FDA clearance for automated insulin delivery and interoperable pump components confers first-mover access ahead of competitors still in review. Reimbursement coverage and CPT/HCPCS coding determine which pump and continuous-delivery systems clinicians can prescribe without imposing out-of-pocket burden on patients, making payer contracting a gating factor for volume growth. Manufacturing scale and quality record also matter for insulin cartridge and pen-needle suppliers competing on tender pricing in public and institutional channels.

The market is led by a group of established players: Novo Nordisk A/S, Eli Lilly and Company, Medtronic plc, Insulet Corporation, Sanofi S.A., Tandem Diabetes Care, Inc., Ypsomed AG, Becton, Dickinson and Company, and F. Hoffmann-La Roche Ltd. These companies hold the broadest combined insulin-formulation and pump-platform portfolios and the deepest guideline and formulary presence.

A second tier of specialists competes on device format and regional reach, including Biocon Ltd., CeQur Corporation, Debiotech SA, Nipro Corporation, Owen Mumford Ltd., Sooil Development Co., Ltd., and Terumo Corporation. Jiangsu Delfu Medical Device Co., Ltd. and Medtrum Technologies Inc., both headquartered in China, compete primarily on domestic tender pricing and expanding pump adoption in Asia-Pacific. Bigfoot Biomedical and Valeritas Holdings, Inc. represent the pipeline of pump and patch-injector entrants pursuing niche indications and delivery formats within the broader device landscape.

Market Evidence

Global insulin delivery device revenue stood at USD 31.339 Billion in 2025, the base year anchoring this report’s decade-long forecast.

That base figure sits inside a longer observation window: sizing for this market has been tracked since 2020, giving the 2025 anchor five years of historical trend behind it and reducing reliance on a single-year snapshot to justify the forecast that follows.

Revenue is estimated at USD 33.79 Billion for 2026, a gain of USD 2.451 Billion over the 2025 base in a single year. That increment equals a 7.82% year-over-year rise – the same rate as the ten-year CAGR – indicating that near-term consumable and device pull-through is already tracking the modeled curve rather than building toward it.

The market is projected to reach USD 66.531 Billion by 2035, more than double the 2025 base value. Absolute dollar growth of that scale over a single decade implies sustained unit-volume expansion across pens, pumps and patch-injector consumables, the kind of recurring-revenue growth that typically funds continued component-supplier and CDMO capacity investment rather than a one-time capital cycle.

A 7.82% CAGR across 2025-2035 is a compounding rate, meaning each successive year adds a larger absolute dollar amount than the one before it – the gap between the 2025 and 2026 values is smaller in dollar terms than the gap that will separate 2034 from 2035, even at a constant percentage rate.

Year	Market Value	Note
2025 (base)	USD 31.339 Billion	Forecast anchor
2026 (current)	USD 33.79 Billion	+7.82% over base
2035 (forecast)	USD 66.531 Billion	2.12x the 2025 base

CAGR, 2025-2035: 7.82%

Key Company Analysis

Companies covered

• Novo Nordisk A/S (profiled below)
• Eli Lilly and Company (profiled below)
• Medtronic plc (profiled below)
• Insulet Corporation (profiled below)
• Sanofi S.A. (profiled below)
• Tandem Diabetes Care, Inc.
• Ypsomed AG
• Becton, Dickinson and Company
• F. Hoffmann-La Roche Ltd
• Bigfoot Biomedical
• Biocon Ltd.
• CeQur Corporation
• Debiotech SA
• Jiangsu Delfu Medical Device Co., Ltd. – China
• Medtrum Technologies Inc. – China
• Nipro Corporation
• Owen Mumford Ltd.
• Sooil Development Co., Ltd.
• Terumo Corporation
• Valeritas Holdings, Inc.

Medtronic plc

Medtronic supplies durable insulin pumps and integrated automated insulin delivery (AID) systems, anchoring the hospital- and endocrinology-channel segment of the insulin delivery devices market. Its MiniMed platform pairs pump hardware with Guardian sensing and hybrid closed-loop algorithms, giving it one of the broader clinically supported AID portfolios among device-only suppliers. Distribution spans North America, Europe, and expanding accounts in Asia Pacific through direct sales and distributor partnerships with diabetes clinics and durable medical equipment providers. Strategy over the forecast period centers on simplifying calibration burden and widening pediatric and type 2 eligibility to defend share against tubeless competitors. In April 2023, the US FDA approved the MiniMed 780G system with an expanded age indication, extending its hybrid closed-loop label.

Insulet Corporation

Insulet’s relevance rests entirely on Omnipod, its tubeless, disposable patch-pump platform that has become a primary growth vehicle within the insulin delivery devices market. Its portfolio is narrower than pump-and-sensor rivals but deeper in tubeless form factor, pairing Omnipod 5 with Dexcom continuous glucose sensors for automated dosing. Channel reach is concentrated in the United States, with growing pharmacy-benefit coverage alongside direct-to-consumer and endocrinology-clinic sales, plus expansion into European and Canadian markets. Strategic direction favors international scaling and broadening the type 2 diabetes label to extend beyond its historical type 1 base. In April 2024, Insulet secured FDA clearance for an expanded Omnipod 5 indication covering type 2 diabetes patients.

Tandem Diabetes Care, Inc.

Tandem competes directly in durable AID pumps, supplying the t:slim X2 and Mobi platforms that integrate with third-party continuous glucose monitors for closed-loop dosing. Its capability position leans on software-driven algorithm updates delivered to installed pumps without hardware replacement, a differentiator against fixed-cycle competitors. Commercial footprint is weighted toward the United States, supplemented by distributor-led sales in Europe and select Asia Pacific markets through endocrinology and specialty-pharmacy channels. Its forward strategy emphasizes miniaturization and smartphone-controlled dosing to compete against tubeless entrants while retaining its algorithm-upgrade advantage. In February 2024, the FDA cleared Tandem Mobi, the company’s smallest durable insulin pump, controllable via a companion mobile application.

Novo Nordisk A/S

Novo Nordisk supplies insulin delivery hardware alongside its insulin formulations, principally through prefilled and durable smart insulin pens rather than pump systems, giving it reach into the injection-based segment of the market. Its capability position combines connected pen technology with dose-tracking software intended to support titration and adherence monitoring for basal-bolus regimens. Geographic and channel footprint is the broadest of its device peers, leveraging existing retail pharmacy and hospital-pharmacy relationships built around its insulin portfolio across developed and emerging markets. Strategic direction over the forecast period favors bundling connected-pen data with digital adherence platforms rather than entering pump hardware directly. In 2024, Novo Nordisk expanded distribution of its NovoPen 6 connected device across additional European markets.

Ypsomed AG

Ypsomed supplies pump hardware and injection devices, with its mylife YpsoPump forming the core of its insulin delivery device relevance, generally delivered in partnership with algorithm and sensor developers rather than as a vertically integrated AID system. Its capability position is narrower in software but competitive in device miniaturization and cartridge-based dosing accuracy. Channel footprint centers on Europe, where reimbursement pathways favor its pump, with contract-manufacturing agreements extending its components into partner-branded systems elsewhere. Strategic direction emphasizes partnership-based hybrid closed-loop expansion rather than proprietary algorithm development. In 2023, Ypsomed’s mylife Loop system, combining its pump with CamDiab’s algorithm, gained expanded European market access.

Profiled here are the five suppliers with the widest position across substrate, converting and filling technology. The full report profiles all 20 companies named above, each to the same structure – business segments, product portfolio, manufacturing footprint, financials, recent developments and SWOT.

Strategic Outlook

The clearest whitespace sits in Europe’s phased hybrid-closed-loop rollout, where NICE TA943 (December 2023) opened NHS access to all under-18s with type 1 diabetes, adults with HbA1c at or above 58 mmol/mol, and pregnant patients. NHS England and NHS Wales committed to a five-year phased rollout from early 2024. The opportunity favors device makers with algorithm-integrated pump-CGM systems already positioned for NHS tendering, contingent on trusts building the clinical capacity to onboard pump-naive patients at the pace HTA approval implies.

By 2035, structure is expected to tilt further from standalone pumps toward connected, algorithm-driven delivery, as payers reward outcomes-linked coverage over device sales alone. Volume-based procurement, demonstrated by China’s NVBP insulin round, signals that drug pricing pressure increasingly pushes competitive differentiation onto the delivery device and attached service layer rather than the insulin molecule itself.

Which Variable Swings the Base Case

The swing variable is the pace of public reimbursement and HTA coverage expansion. A faster path – NICE-style technology appraisals replicated across additional national systems, and IRA-style beneficiary cost caps extended beyond Medicare Part B – would push adoption above the 7.82% base case by converting the large undiagnosed and underinsured pools in the Middle East, Africa and South America into treated, device-using patients. A slower path drags growth below base case: continued absence of public pump and CGM coverage in systems like Brazil’s SUS, combined with procurement bodies extending China’s insulin price-compression model into device tenders, would compress both volume growth and average selling price simultaneously.

Market Sizing Approach

The USD 31.339 Billion base-year (2025) valuation and the 7.82% CAGR to USD 66.531 Billion by 2035 represent a single internally constructed quantitative benchmark for this market. Historical data from 2020 onward and the current-year estimate of USD 33.79 Billion (2026) are held to that same benchmark throughout; no conflicting external sizing is introduced at the segment, regional or country level.

The total is built bottom-up from measurable demand units rather than assumed top-down. The base layer is the installed base of insulin delivery devices – pens, pumps and patch systems in active patient use – segmented by device class. Each installed unit is multiplied by its utilisation rate and by consumable pull-through: cartridges, pen needles, infusion sets and sensor components replaced on a recurring cycle. This device-times-consumable logic is run separately for each product type and end-user setting (hospital, homecare, ambulatory), then aggregated to the segment level, and segments are summed to the global total, cross-checked against the treated insulin-dependent population implied by the base-year figure.

The forecast to 2035 is driven by variables specific to this market: the diagnosed and insulin-treated diabetic population trend, the pace of smart-pen and connected-pump approvals moving through FDA and EMA pathways, the patent expiry schedule for reference insulin products and the resulting biosimilar-insulin entry, and anticipated reimbursement or coverage-code changes affecting device replacement cycles. Each variable is applied against the base-year installed base to project unit growth and consumable pull-through through the 2025-2035 window.

Insulin Delivery Devices Market Report Scope

Attribute	Detail
Market Size 2025	31.34 (USD Billion)
Market Size 2026	33.79 (USD Billion)
Market Size 2035	66.53 (USD Billion)
Compound Annual Growth Rate (CAGR)	7.82% (2026 to 2035)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Segment Analysis and Trends
Base Year	2025
Market Forecast Period	2026 – 2035
Historical Data	2020 – 2025
Market Forecast Units	USD Billion
Key Companies Profiled	Novo Nordisk A/S; Eli Lilly and Company; Medtronic plc; Insulet Corporation; Sanofi S.A.; Tandem Diabetes Care, Inc.; Ypsomed AG; Becton, Dickinson and Company; F. Hoffmann-La Roche Ltd; Bigfoot Biomedical; Biocon Ltd.; CeQur Corporation
Segments Covered	By Product Type, By Technology / Connectivity, By Patient Age Group, By Distribution Channel, By End User
Key Market Opportunities	Reimbursement expansion for hybrid closed-loop systems under national HTA pathways, paired with unmet pump and CGM access across South America and the Middle East, marks the clearest whitespace.
Key Market Dynamics	National volume-based procurement in China is compressing device and consumable pricing even as payer and HTA coverage decisions widen reimbursed access to automated insulin delivery.
Regions Covered	North America, Europe, Asia-Pacific, Middle East and Africa, South America

Market Insights

Frequently Asked Questions

Explore key insights into the Insulin Delivery Devices Market, including market size, growth outlook, regional trends, leading product segments, key players, reimbursement, challenges, and regulatory requirements.

01 How big is the Insulin Delivery Devices Market?

The Insulin Delivery Devices Market was valued at USD 31.339 Billion in 2025. This base covers the global installed use of insulin pens, pumps, syringes, and needle-free injectors across hospital, retail, and homecare channels for type 1 and type 2 diabetes management.

02 What is the growth forecast for the Insulin Delivery Devices Market?

The market is projected to reach USD 66.531 Billion by 2035, up from USD 31.339 Billion in 2025, representing a CAGR of 7.82% across 2025–2035. Insulin pumps compound fastest within that span, forecast at an 11.33% CAGR as hybrid closed-loop adoption widens.

03 Which region holds the largest share of the Insulin Delivery Devices Market?

Europe held 28.0% of the market in 2025, equivalent to USD 8.775 Billion, supported by NHS and national payer coverage for insulin pumps and hybrid closed-loop systems across Germany, France, and the United Kingdom. Coverage decisions directly influence device uptake across the region.

04 Which region is growing fastest in the Insulin Delivery Devices Market?

Asia-Pacific is set for the fastest regional growth, led by China, India, Japan, and South Korea. China’s National Volume-Based Procurement reduced average insulin prices by 48% from 2022, widening affordable access across a region with a large diagnosed and undiagnosed diabetic population.

05 Which segment leads the Insulin Delivery Devices Market?

Insulin pens led by product type with a 52.44% share in 2025, favoured for dosing simplicity and lower training requirements than pumps. Insulin pumps are the fastest-expanding category, forecast at an 11.33% CAGR as hybrid closed-loop systems gain payer coverage.

06 What is driving growth in the Insulin Delivery Devices Market?

Growth stems from expanding reimbursement, including the Medicare Part B USD 35 monthly insulin-pump coinsurance cap under IRA Section 11407, and from the shift toward homecare self-administration. Homecare is the leading end-use setting at a 43.67% share and is also the fastest-growing at a 10.45% CAGR.

07 Who are the key players in the Insulin Delivery Devices Market?

Leading suppliers include Novo Nordisk A/S, Eli Lilly and Company, Medtronic plc, Insulet Corporation, Sanofi S.A., Tandem Diabetes Care, Inc., Ypsomed AG, and Becton, Dickinson and Company. These companies span insulin pens, patch pumps, hybrid closed-loop systems, and pen needles.

08 How does reimbursement affect adoption in the Insulin Delivery Devices Market?

Coverage decisions directly influence device uptake. NICE TA943 recommends hybrid closed-loop systems for all UK patients under 18 with type 1 diabetes under a phased NHS rollout from early 2024, while IRA Section 11407 caps US Medicare Part B insulin-pump coinsurance at USD 35 per month.

09 What are the main challenges facing the Insulin Delivery Devices Market?

Access gaps persist outside reimbursed systems. Brazil’s public SUS network excludes insulin pumps and continuous glucose monitors from coverage, leaving patients reliant on manual glucose testing. Elsewhere, national procurement such as China’s 48% average price reduction can compress supplier margins even as unit volumes expand.

10 What regulatory approvals are required for insulin delivery devices?

Insulin pumps, pens, and needle-free injectors typically clear the US FDA 510(k) or PMA pathway alongside EU MDR conformity marking for the European market. Reimbursement- linked health technology assessment, such as NICE’s TA943 appraisal of hybrid closed-loop systems, can function as a further gate before national rollout.